ATRAAtara Biotherapeutics, Inc.

Nasdaq atarabio.com


$ 0.69 $ -0.01 (-1.4 %)    

Friday, 26-Apr-2024 15:57:03 EDT
QQQ $ 431.01 $ 6.55 (1.54 %)
DIA $ 382.27 $ 1.39 (0.36 %)
SPY $ 508.26 $ 4.77 (0.95 %)
TLT $ 88.26 $ 0.46 (0.52 %)
GLD $ 216.60 $ 0.70 (0.32 %)
$ 0.69
$ 0.70
$ 0.00 x 0
$ 0.00 x 0
$ 0.68 - $ 0.71
$ 0.20 - $ 3.02
526,741
na
73.08M
$ 1.53
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 03-28-2024 12-31-2023 10-K
2 11-01-2023 09-30-2023 10-Q
3 08-08-2023 06-30-2023 10-Q
4 05-08-2023 03-31-2023 10-Q
5 02-08-2023 12-31-2022 10-K
6 11-08-2022 09-30-2022 10-Q
7 08-08-2022 06-30-2022 10-Q
8 05-05-2022 03-31-2022 10-Q
9 02-28-2022 12-31-2021 10-K
10 11-04-2021 09-30-2021 10-Q
11 08-09-2021 06-30-2021 10-Q
12 05-04-2021 03-31-2021 10-Q
13 03-01-2021 12-31-2020 10-K
14 11-09-2020 09-30-2020 10-Q
15 08-05-2020 06-30-2020 10-Q
16 05-06-2020 03-31-2020 10-Q
17 02-27-2020 12-31-2019 10-K
18 11-07-2019 09-30-2019 10-Q
19 08-08-2019 06-30-2019 10-Q
20 05-09-2019 03-31-2019 10-Q
21 02-26-2019 12-31-2018 10-K
22 11-06-2018 09-30-2018 10-Q
23 08-01-2018 06-30-2018 10-Q
24 05-08-2018 03-31-2018 10-Q
25 02-27-2018 12-31-2017 10-K
26 11-09-2017 09-30-2017 10-Q
27 08-07-2017 06-30-2017 10-Q
28 05-04-2017 03-31-2017 10-Q
29 03-09-2017 12-31-2016 10-K
30 11-04-2016 09-30-2016 10-Q
31 08-08-2016 06-30-2016 10-Q
32 05-06-2016 03-31-2016 10-Q
33 03-04-2016 12-31-2015 10-K
34 11-06-2015 09-30-2015 10-Q
35 08-07-2015 06-30-2015 10-Q
36 05-11-2015 03-31-2015 10-Q
37 02-26-2015 12-31-2014 10-K
38 11-12-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 stifel-maintains-hold-on-atara-biotherapeutics-lowers-price-target-to-23

Stifel analyst Benjamin Burnett maintains Atara Biotherapeutics (NASDAQ:ATRA) with a Hold and lowers the price target from $...

 atara-biotherapeutics-q4-eps-056-misses-048-estimate-sales-425m-miss-1155m-estimate

Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.56) per share which missed the analyst consensus estimate ...

 atara-biotherapeutics-receives-fda-clearance-of-ind-application-in-lupus-nephritis-for-ata3219

Second IND Clearance for ATA3219 Following Non-Hodgkin's Lymphoma (NHL) and First in an Autoimmune Disease IndicationInitia...

 atara-biotherapeutics-announces-submission-of-investigational-new-drug-application-for-ata3219-for-treatment-of-lupus-nephritis

ATA3219 is an Allogeneic CAR T-Cell Therapy Targeting CD19+ B Cells to Potentially Address the Root Cause of Lupus Nephritis (L...

 why-4d-molecular-therapeutics-shares-are-trading-higher-by-20-here-are-20-stocks-moving-premarket

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ: FDMT) rose sharply in today’s pre-market trading. 4DMT presented interim da...

 reported-late-wednesday-atara-biotherapeutics-and-pierre-fabre-laboratories-announced-the-publication-of-phase-3-allele-tab-cel-data-in-the-lancet-oncology

First Phase 3 Results Published for an Allogeneic T-Cell Therapy Significant 51.2% Objective Response Rate and 23.0 Month Me...

 why-aar-shares-are-trading-lower-by-7-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of AAR Corp. (NYSE: AIR) fell during Friday’s session after the company reported mixed second-quarter financial results.

 why-rocket-lab-shares-are-trading-higher-by-15-here-are-20-stocks-moving-premarket

Shares of Rocket Lab USA, Inc. (NASDAQ: RKLB) shares rose sharply in pre-market trading after the company announced a new $515...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION